LAWSUITS NEWS & LEGAL INFORMATION
Testosterone Therapy Class Action Lawsuit Filed
New York, NY: A potential class action lawsuit has been filed on behalf of men who have suffered heart attack, stroke or other serious heart problems allegedly due to their use of prescription low testosterone therapies.
The complaint was filed by a man who allegedly suffered a heart attack after using AndroDerm and Depo Testosterone for several years. The named defendants in the lawsuit are Actavis Inc, Watson Pharmaceuticals Inc., Pfizer Inc. and Pharmacia & Upjohn Co. The plaintiff has filed the class action on behalf of allmen who allegedly suffered serious injury or death due to their use of AndroDerm and Depo Testosterone. The lawsuit, McGill, et ux. v. Actavis Inc., et al., No. 2:14-2177, was filed in the U.S. District Court, Eastern District of Pennsylvania.
The lawsuit was filed as a result of the U.S. Food & Drug Administration (FDA) announcement in January stating the agency is investigating heart risks potentially associated with this class of medications. The FDA review was prompted by the publication of research that suggested the use of testosterone increases the risk of heart attack, strokes, and death in men over 65-years-old, as well as in younger men with pre-existing heart disease.
Among the allegations, the plaintiff claims the manufacturers of AndroDerm and Depo Testosterone of engaged in an aggressive unbranded 'disease awareness' campaign to alert men that they might be suffering from low testosterone. As a result of this alleged "disease mongering,"the number of men diagnosed with low testosterone increased dramatically, and sales of AndroDerm and Depo Testosterone rose to several hundred million dollars, according to the lawsuit. Further, the drug makers are allegedly liable for misrepresenting AndroDerm and Depo Testosterone as safe and effective treatment for low testosterone, when, they can cause cardiac events, strokes and thrombolytic events, the lawsuit claims.
Published on Apr-25-14
The complaint was filed by a man who allegedly suffered a heart attack after using AndroDerm and Depo Testosterone for several years. The named defendants in the lawsuit are Actavis Inc, Watson Pharmaceuticals Inc., Pfizer Inc. and Pharmacia & Upjohn Co. The plaintiff has filed the class action on behalf of allmen who allegedly suffered serious injury or death due to their use of AndroDerm and Depo Testosterone. The lawsuit, McGill, et ux. v. Actavis Inc., et al., No. 2:14-2177, was filed in the U.S. District Court, Eastern District of Pennsylvania.
The lawsuit was filed as a result of the U.S. Food & Drug Administration (FDA) announcement in January stating the agency is investigating heart risks potentially associated with this class of medications. The FDA review was prompted by the publication of research that suggested the use of testosterone increases the risk of heart attack, strokes, and death in men over 65-years-old, as well as in younger men with pre-existing heart disease.
Among the allegations, the plaintiff claims the manufacturers of AndroDerm and Depo Testosterone of engaged in an aggressive unbranded 'disease awareness' campaign to alert men that they might be suffering from low testosterone. As a result of this alleged "disease mongering,"the number of men diagnosed with low testosterone increased dramatically, and sales of AndroDerm and Depo Testosterone rose to several hundred million dollars, according to the lawsuit. Further, the drug makers are allegedly liable for misrepresenting AndroDerm and Depo Testosterone as safe and effective treatment for low testosterone, when, they can cause cardiac events, strokes and thrombolytic events, the lawsuit claims.
Testosterone Stroke and Testosterone Heart attack Legal Help
If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Published on Apr-25-14
TESTOSTERONE THERAPY CLASS ACTION LAWSUIT LEGAL ARTICLES AND INTERVIEWS
Testosterone Bellwether Trials Chosen
September 1, 2016
Chicago, IL: For the men who filed testosterone lawsuits alleging they suffered serious side effects as a result of testosterone therapy, news that litigation is moving forward will be welcomed. Eight bellwether cases have been chosen and an initial trial date set for 2017. Claims surrounding testosterone therapy include allegations the therapy is linked to an increased risk of myocardial infarction and venous thromboembolism. READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READER COMMENTS
Robert
on
Roy Banta
on
British Columbia
on
Arizona
on
Anonymous
on
Anonymous
on
Something that contributes to the suicides of male chronic pain patients, is most physicians who treat chronic pain refuse to test Testosterone in male patients.
Pain patients are depressed enough from their chronic pain, then they're given opioid pain medications, that deplete their Testosterone. Low One thing I feel contributes to the suicides of male chronic pain patients, is that pain doc's won't test Testosterone. Pain patients are depressed enough, without being given opioid pain medications that depletes their Testosterone. Low Testosterone not only makes patients more depressed, they have no energy, have problems building muscle, and moodswings.
For me it was like I was 8 years old, I didn't think girls are icky, I just have no interest in my wife sexually. It's also creates problems in relationships, it's hormones, so the guy doesn't understand what's going on, for the wife, if their husband isn't making love to them, they're either cheating, or don't love them anymore. Neither one is good for the relationship.
The failure to prescribe Testosterone to pain patients, is causing an increase in suicides. When you add the problems pain patients have getting medications now, next year will see a significant increase in suicides.
Texas
on